Does Rallies show Form 4 insider transactions for LH?

Yes. Rallies tracks LH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LH. It does not provide personalized investment advice.

LH (Labcorp Holdings Inc.) Stock Analysis - Insider Trades

Labcorp Holdings Inc. (LH) is a publicly traded Healthcare sector company. As of May 20, 2026, LH trades at $254.87 with a market cap of $20.96B and a P/E ratio of 22.31. LH moved +0.39% today. Year to date, LH is +0.81%; over the trailing twelve months it is +1.56%. Its 52-week range spans $209.38 to $293.72. Analyst consensus is strong buy with an average price target of $310.78. Rallies surfaces LH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LH stock inside the company?

Recent LH insider activity includes Schechter Adam H sold 5.90K, Wilkinson Peter J sold 1.63K, Meltzer Jonathan C sold 839, Schechter Adam H sold 8.71K, and van der Vaart Sandra D sold 547.54. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LH Key Metrics

Key financial metrics for LH
Metric	Value
Price	$254.87
Market Cap	$20.96B
P/E Ratio	22.31
EPS	$11.36
Dividend Yield	0.72%
52-Week High	$293.72
52-Week Low	$209.38
Volume	135.35K
Avg Volume	0
Revenue (TTM)	$14.14B
Net Income	$942.70M
Gross Margin	28.83%

Recent LH Insider Trades

Schechter Adam H sold 5.90K (~$1.50M) on May 11, 2026.
Wilkinson Peter J sold 1.63K (~$436.09K) on Mar 27, 2026.
Meltzer Jonathan C sold 839 (~$224.05K) on Mar 27, 2026.
Schechter Adam H sold 8.71K (~$2.44M) on Mar 3, 2026.
van der Vaart Sandra D sold 547.54 (~$156.00K) on Feb 27, 2026.

Latest LH News

Labcorp Unveils MyLabcorp AI App for Lab Results, Trend Tracking and Scheduling — May 20, 2026
Labcorp surges after Q1 beat and higher 2026 EPS guidance — Apr 30, 2026
Labcorp Q1 Revenue Up 5.8% to $3.54B, Lifts Full-Year EPS Guidance — Apr 30, 2026
Labcorp slides ahead of April 30 earnings as traders de-risk positions — Apr 23, 2026
Labcorp Launches FDA-Approved PD-L1 Test for Keytruda in Ovarian Cancer — Apr 22, 2026

LH Analyst Consensus

10 analysts cover LH: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $310.78.

Common questions about LH

Who is trading LH stock inside the company?: Recent LH insider activity includes Schechter Adam H sold 5.90K, Wilkinson Peter J sold 1.63K, Meltzer Jonathan C sold 839, Schechter Adam H sold 8.71K, and van der Vaart Sandra D sold 547.54. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LH?: Yes. Rallies tracks LH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LH. It does not provide personalized investment advice.